Kiniksa Pharmaceuticals International (KNSA) Depreciation & Amortization (CF) (2020 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $472000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Depreciation & Amortization (CF) rose 31.84% year-over-year to $472000.0; the trailing twelve-month figure through Jun 2026 stood at $1.8 million (up 19.24% YoY), and the FY2025 full-year result was $1.6 million, down 8.32% from the prior year.
• Depreciation & Amortization (CF) rose to $472000.0 in Q2 2026 per KNSA's latest filing, from $468000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $656000.0 in Q1 2022 and bottomed at $345000.0 in Q1 2025.
• Historically, Depreciation & Amortization (CF) has averaged $496222.2 across 5 years, with a median of $470000.0 in 2026.
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) jumped 110.26% in 2022, then tumbled 33.83% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $602000.0 in 2022, then fell by 10.3% to $540000.0 in 2023, then retreated by 25.93% to $400000.0 in 2024, then climbed by 16.75% to $467000.0 in 2025, then gained by 1.07% to $472000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $472000.0, $468000.0, and $467000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.